Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

381. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis

Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews (...) of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards evidence-based guidelines for the prevention

2005 Health Technology Assessment (HTA) Database.

382. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event

Oral anticoagulation strategies after a first idiopathic venous thromboembolic event Oral anticoagulation strategies after a first idiopathic venous thromboembolic event Oral anticoagulation strategies after a first idiopathic venous thromboembolic event Aujesky D, Smith K J, Roberts M S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined six strategies for the treatment of 40- to 80-year-old men and women after their first idiopathic venous thromboembolic event or pulmonary embolism (PE) and after a standard 3-month course of conventional-intensity anticoagulation therapy with warfarin. Strategy 1 was the discontinuation of anticoagulation (i.e. the 3-month strategy). Strategy 2 was conventional-intensity

2005 NHS Economic Evaluation Database.

383. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care (...) study Menzin J, Boulanger L, Hauch O, Friedman M, Marple C B, Wygant G, Hurley J S, Pezzella S, Kaatz S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the costs and outcomes from anticoagulation clinics in three

2005 NHS Economic Evaluation Database.

384. Perioperative anticoagulation for patients with mechanical heart valves: a model comparing unfractionated and low-molecular-weight heparin

Perioperative anticoagulation for patients with mechanical heart valves: a model comparing unfractionated and low-molecular-weight heparin Perioperative anticoagulation for patients with mechanical heart valves: a model comparing unfractionated and low-molecular-weight heparin Perioperative anticoagulation for patients with mechanical heart valves: a model comparing unfractionated and low-molecular-weight heparin Garcia D A, Libby E N, Rich J S Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of intravenous (IV) unfractionated heparin (UFH) and low molecular weight heparins (LMWH) for short-term perioperative anticoagulation in patients with mechanical heart valves undergoing invasive procedures. Type

2005 NHS Economic Evaluation Database.

385. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. (PubMed)

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. BACKGROUND: The risk for atrial fibrillation-associated stroke increases at low anticoagulation intensities. However, higher intensities increase hemorrhage risk. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity. OBJECTIVE: To examine (...) the relationship of age, anticoagulation intensity, and risk for intracranial hemorrhage. DESIGN: Case-control study. SETTING: Academic medical center. PATIENTS: 170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation. MEASUREMENTS: The authors performed multivariable conditional logistic regression to determine the odds of intracranial hemorrhage with regard to age

2004 Annals of Internal Medicine

386. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. (PubMed)

Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. BACKGROUND: Negative results on simplified compression ultrasonography cannot rule out symptomatic deep venous thrombosis (DVT) without further testing, such as repeated ultrasonography several days later. Repeated testing is costly and inconvenient, and patients are sometimes less likely to return for follow-up tests. OBJECTIVE: To determine the rate of venous (...) thromboembolism when anticoagulation is withheld in patients with symptoms of DVT of the leg after negative results on a single examination with comprehensive duplex ultrasonography. DESIGN: Prospective clinical cohort study. SETTING: Peripheral vascular laboratory of a tertiary care academic hospital. PATIENTS: 445 consecutive patients in whom a first episode of symptomatic DVT was suspected. INTERVENTION: The researchers examined the entire leg with comprehensive duplex ultrasonography, using compression

2004 Annals of Internal Medicine

387. Resolution of left atrial thrombus after 6 months of anticoagulation in candidates for percutaneous transvenous mitral commissurotomy. (PubMed)

Resolution of left atrial thrombus after 6 months of anticoagulation in candidates for percutaneous transvenous mitral commissurotomy. BACKGROUND: Resolution of left atrial thrombus after long-term oral anticoagulation enhances safe percutaneous transvenous mitral commissurotomy (PTMC); however, the short-term benefit has not been defined. OBJECTIVES: To estimate the resolution rate of left atrial thrombus among PTMC candidates after 6 months of oral anticoagulation and to determine its main (...) thrombus size of 1.6 cm2 or less, a left atrial spontaneous echocardiographic contrast grade of 1 or less, and an international normalized ratio (INR) of at least 2.5. Patients with all of these predictors had a 94.4% chance of complete thrombus resolution (CI, 84.4% to 98.1%). CONCLUSIONS: After 6 months of oral anticoagulation, the left atrial thrombus disappeared in about a quarter of PTMC candidates so they could safely undergo PTMC. Less clinical severity, lower grading of the left atrial

2004 Annals of Internal Medicine

388. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. (PubMed)

Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. BACKGROUND: People with nonrheumatic atrial fibrillation (NRAF) who have had a transient ischaemic attack (TIA) or a minor ischaemic stroke are at high risk of recurrent stroke. OBJECTIVES: The objective of this review was to assess the effect of anticoagulants for secondary prevention, after a stroke or TIA, in patients with NRAF. SEARCH STRATEGY: We (...) searched the Cochrane Stroke Group trials register (9 June 2003) and contacted trialists. SELECTION CRITERIA: Randomised trials comparing oral anticoagulants with control (no therapy) or placebo in people with NRAF and a previous TIA or minor ischaemic stroke. Control groups on aspirin did not meet the selection criteria. DATA COLLECTION AND ANALYSIS: Both reviewers assessed trial quality and extracted data. MAIN RESULTS: Two trials involving 485 people were included. Follow-up time was 1.7 years

2004 Cochrane

389. Optimal antithrombotic management of anticoagulated patients with a history of myocardial infarction

Optimal antithrombotic management of anticoagulated patients with a history of myocardial infarction Optimal antithrombotic management of anticoagulated patients with a history of myocardial infarction Optimal antithrombotic management of anticoagulated patients with a history of myocardial infarction Gibbs W J, Fugate S E, Vesta K S CRD summary This review assessed the efficacy and safety of oral anticoagulation, with or without aspirin, for secondary prevention of myocardial infarction (...) . The authors concluded that oral anticoagulation was at least as effective as aspirin, but there was insufficient evidence for combined treatment versus oral anticoagulation alone. Limitations in the reporting and analysis of the results make it difficult to adequately assess the robustness of these conclusions. Authors' objectives To assess the efficacy and safety of oral anticoagulation, with and without aspirin, for the secondary prevention of myocardial infarction (MI). Searching MEDLINE (1966

2004 DARE.

390. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy

Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging (...) in patients receiving long-term oral anticoagulant therapy Spyropoulos A C, Frost F J, Hurley J S, Roberts M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of low molecular weight heparin (LMWH) during the perioperative period

2004 NHS Economic Evaluation Database.

391. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions

Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions Bond C (...) A, Raehl C L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined pharmacist-managed anticoagulation treatment with heparin and warfarin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

2004 NHS Economic Evaluation Database.

392. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis

The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis Gerson L B, Triadafilopoulos G, Gage B F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Seven strategies for the management of anticoagulants in the periendoscopic period for patients with atrial fibrillation were investigated. The strategies were as follows. Continue warfarin: a colonoscopy was performed without interrupting warfarin therapy. Hold warfarin

2004 NHS Economic Evaluation Database.

393. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation

Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous (...) -infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation Fanikos J, Tsilimingras K, Kucher N, Rosen A B, Hieblinger M D, Goldhaber S Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health

2004 NHS Economic Evaluation Database.

394. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. (PubMed)

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. BACKGROUND: The incidence of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR. METHODS: We studied (...) percent confidence interval, 1.1 to 10.1). An INR of 1.5 to 1.9 at admission was associated with a mortality rate similar to that for an INR of less than 1.5 (18 percent and 15 percent, respectively). The 30-day mortality rate among patients who were taking aspirin at the time of the stroke was similar to that among patients who were taking warfarin and who had an INR of less than 2.0. CONCLUSIONS: Among patients with nonvalvular atrial fibrillation, anticoagulation that results in an INR of 2.0

2003 NEJM

395. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Clinical impact of bleeding in pa... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2003 ) Volume: 139 , Issue: 11 , Publisher: Am Coll Physicians , Pages: 893-900 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Clinicians should consider the clinical (...) impact of anticoagulant-related bleeding when deciding on the duration of anticoagulant therapy in patients with venous thromboembolism. PURPOSE: To provide reliable estimates of the clinical impact of anticoagulant-related bleeding, defined as the case-fatality rate of major bleeding and the risk for intracranial bleeding. DATA SOURCES: MEDLINE (January 1989 to May 2003), Cochrane Controlled Trial Registry, thromboembolism experts, and reference lists; English-language literature only. STUDY

2003 Annals of Internal Medicine

396. Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment

Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment de Sola-Morales O Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation de Sola-Morales O. Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN06/2003. 2003 Authors' objectives The endpoints of this study were to evaluate

2003 Health Technology Assessment (HTA) Database.

397. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants

Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants (...) Iorio A, Guercini F, Pini M CRD summary This review compared long term low molecular weight heparin (LMWH) treatment of venous thromboembolism with oral anticoagulation. The authors concluded that LMWH for 3 months is as safe and effective as oral anticoagulation in preventing the recurrence of venous thromboembolism. The authors' conclusions are likely to be reliable. Authors' objectives To compare the efficacy and safety of long term treatment of venous thromboembolism (VTE) using

2003 DARE.

398. Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis

Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis Mathew A, Riley T R, Young M, Ouyang A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three management strategies for anticoagulation in patients undergoing an urgent or elective endoscopy were considered. The first was an initial diagnostic endoscopy without altering anticoagulation therapy, followed by therapeutic endoscopy if required. The second option was termed the "heparin window approach". This involved

2003 NHS Economic Evaluation Database.

399. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. (PubMed)

Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. BACKGROUND: Bleeding associated with warfarin anticoagulation correlates directly to duration and degree of international normalized ratio (INR) elevation above the therapeutic range. Safe and rapid reversal of excessive anticoagulation is occasionally needed to treat or avoid hemorrhagic complications. OBJECTIVE: To evaluate the efficacy and safety of human recombinant factor VIIa (rFVIIa (...) ) concentrate in persons requiring rapid reversal of the effects of warfarin. DESIGN: Uncontrolled case series. SETTING: Academic medical center. PATIENTS: 13 patients with critically increased INRs requiring immediate reversal of warfarin-induced anticoagulation. MEASUREMENTS: Prothrombin time and INR were measured before and after administration of varying doses of rFVIIa. RESULTS: Critically prolonged INR and bleeding complications were treated successively and rapidly in all patients, regardless

2002 Annals of Internal Medicine

400. Oral anticoagulation and risk of death: a medical record linkage study. (PubMed)

Oral anticoagulation and risk of death: a medical record linkage study. OBJECTIVE: To study how mortality varies with different degrees of anticoagulation reflected by the international normalised ratio (INR). DESIGN: Record linkage analysis with death hazard estimated as a continuous function of INR. DATA SOURCES: 46 anticoagulation clinics in Sweden with computerised medical records. SUBJECTS: Records for 42 451 patients, 3533 deaths, and 1.25 million INR measurements. MAIN OUTCOME MEASURES (...) , 1069 deaths occurred within 7 weeks; if the risk coincided with that with an INR of 2.9, the expected number of deaths would have been 569. Thus at least 500 deaths were associated with a high INR value, but not necessarily caused by the treatment. CONCLUSIONS: The excess mortality associated with high INR values supports the use of less intensive treatment and a small therapeutic window, with INR close to 2.2-2.3 irrespective of the indication for anticoagulant treatment. More preventive actions

Full Text available with Trip Pro

2002 BMJ